"Using the XFe96 Analyzer will enable me to decipher the different pathways of cancer cell metabolism, particularly under hypoxic conditions, which I believe is a key to new therapeutic strategies," added Dr. Gottlieb. "Once I realized that I could measure the dynamics of cancer metabolism in real-time, in a hypoxic environment, I knew we needed this technology."
"Whenever we are able to bring together the best minds with enabling technologies we know that good things will come of it. Innovative scientific collaborations play a crucial role in finding ways to unlock the potential of new therapies, and the Beatson Institute has a strong heritage of research excellence in cancer research," said David Ferrick, Ph.D., Chief Scientific Officer at Seahorse Bioscience. "We are excited to work with the Beatson Institute, and hope that in utilizing the power of the XF Analyzer they will gain greater understanding and potentially new discoveries regarding cancer metabolism."
Marketing Communications Manager
About Seahorse Bioscience
Seahorse XF instruments are the standard in cellular bioenergetic measurements. More than 700 scientists in 23 countries are utilizing the award-winning XF Analyzers to advance their research into the role of cell metabolism and its implications in cancer, aging, and metabolic, cardiovascular, and neurodegenerative diseases. Seahorse is headquartered in Billerica, MA. For more information, visit http://www.seahorsebio.com.
About the Beatson Institute for Cancer Research
As one of Cancer Research UK's core-funded institutes,
|SOURCE Seahorse Bioscience|
Copyright©2012 PR Newswire.
All rights reserved